Jianping Xiong

机构：Memorial Sloan Kettering Cancer Center, Nanchang University, Jiangxi University of Technology, Shantou University, First Affiliated Hospital of Jiangxi Medical College, Jiangxi Provincial Cancer Hospital, Guangxi Science and Technology Department, Jiangxi Maternal and Child Health Hospital, First Affiliated Hospital of Shantou University Medical College, Guangxi Transportation Research Institute, First Affiliated Hospital of Nanchang University, Nanjing Medical University · ORCID：0000-0003-0398-6090

发表论文 287 篇 · 总被引 12441 次 · h-index 51

代表论文

• p53 induces circFRMD4A to suppress cancer development through glycolytic reprogramming and cuproptosis (2024 · Molecular Cell · 被引 63)
• Indole derivatives ameliorated the methamphetamine-induced depression and anxiety via aryl hydrocarbon receptor along “microbiota-brain” axis (2025 · Gut Microbes · 被引 51)
• Targeting HGF/c-MET signaling to regulate the tumor microenvironment: Implications for counteracting tumor immune evasion (2025 · Cell Communication and Signaling · 被引 49)
• Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial (2025 · Nature Medicine · 被引 30)
• Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study (2024 · Journal for ImmunoTherapy of Cancer · 被引 26)
• Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study (2025 · The Lancet Oncology · 被引 24)